Sharps Technology signs 5-year, $200M syringe SA with Nephron

Sharps Technology announces the signing of a 5-year, $200 million syringe Sales Agreement, SA, with Nephron Pharmaceuticals to complement the Company’s Asset Purchase Agreement, APA, to acquire the InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina. The facility will be the only fully dedicated, specialized COC prefillable syringe manufacturing plant in North America and was designed with innovative manufacturing capabilities to produce high-demand, specialty syringe systems. Product delivery is scheduled to begin late in the second quarter of 2025, with projected revenue totaling approximately $37 million for the first 12 months of sales.